HERE is considerable evidence that links TBI and AD. Several epidemiological studies have demonstrated that TBI is an epigenetic risk factor for the development of AD. 5, [11] [12] [13] 18, 21 In addition, plaques composed of A␤ have been found within days after a single incident of TBI in humans, similar to the hallmark pathological characteristics of plaque in cases of AD. 6, 19 Nonetheless, mechanisms underlying the potential relationship have yet to be elucidated. Using an inertial brain injury model in pigs that produces diffuse axonal injury, large accumulations of A␤ in damaged axons were found to be distributed throughout the brain, 23 suggesting a potential source of A␤ for plaque formation. In the present study, the research team questioned whether A␤ accumulation in axons also occurs in brain-injured humans and if this pathological finding is coincident with A␤ plaque formation.
Semiquantitative Analysis
To explore the relationships between the extent of pathological changes and the age of the patient, postinjury survival interval, and ApoE genotype for each case, the number of immunoreactive profiles of axonal bulbs, plaques, neurons, and corpora amylacea were determined in a semiquantitative fashion by applying a ranked scale. This was done by an observer blinded to the circumstances of each case, as has been described previously in detail. 23, 26 Only immunoreactive profiles that could be clearly identified based on morphological characteristics were counted in each section. These profiles were counted in three to five fields (each field measuring ~ 1.2 mm 2 ) for each brain section and an average for each profile type was determined per field. A simple scale was used to express the extent of damage in each case in the following manner: ϩ, fewer than five profiles; ϩϩ, six to 15 profiles; and ϩϩϩ, more than 15 profiles.
Results

Axonal Pathology
No axonal injury or plaquelike profiles were detected by any stain in the control brains. In brain sections obtained from the 12 brain-injured patients, varying densities of axonal bulbs and axonal swellings were observed following trauma (18 hours-9 days postinjury), with a relatively high density of axonal damage found in 10 patients with brain injuries (Fig. 1A-C, Table 3 ). These axonal lesions were identified by antibodies targeting NF protein (N52 and SMI-31) and APP (22C11). In nine of these cases, extensive A␤ immunoreactivity was found in the terminal swellings of disconnected axons, which was elucidated by the following antibodies: amyloid 1-17, amyloid C-20, 2332, 13335, and BC05. Double immunostaining demonstrated colocalization of immunoreactivity of A␤ with APP and NF protein in the axonal bulbs ( Fig. 2A-L) . Although all A␤-immunoreactive axons colabeled with APP and NF immunoreactivity, many varicose axonal swellings only stained for APP and NF. For many A␤-immunoreactive axons, we also observed a dissemination of A␤ immunoreactivity into the surrounding tissue. In three head-injured patients, A␤ immunoreactivity was not detected, despite the identification of extensive axonal damage (Table 3) .
Plaquelike Profiles Immunoreactive for A␤
In eight specimens obtained in brain-injured patients that demonstrated A␤ immunoreactivity in axons, plaquelike profiles immunoreactive for A␤ were identified in the cortex by using the antibodies 2332, 13335, 4G8, ␤A27, 6F/ 3D, and BC05 ( Fig. 1D and E, Fig. 2M -O, and Table 3 ). Some A␤ plaquelike profiles were also found in the white 33, M 31 hrs ATB * ATB = acute tracheobronchitis; CL = cirrhosis of liver; DAI = diffuse traumatic axonal injury severity grades 0-3; EDH = extradural hematoma; FL = fatty liver; IBD = ischemic brain damage; ICH = intracranial hematoma; MF = multiple fractures; MI = multiple injuries; mod = moderate; NK = not known; PM = postmortem; rICP = raised intracranial pressure; RTA = road traffic accident; SDH = subdural hematoma; SS = septicemic shock. 
Accumulation of A␤ and APP in Neurons
In seven specimens obtained in brain-injured patients, immunoreactivity for A␤ and APP was identified in the cytoplasm of neurons throughout the cortex by using the antibodies 2332, 13335, amyloid 1-17, amyloid C-20, and 6F3D ( Fig. 1G and H, Fig. 2P -R, and Table 3 ).
Immunoreactivity for A␤ and NF in the Corpora Amylacea
In nine specimens obtained from brain-injured patients, immunoreactivity for A␤ and NF protein was found in discrete round profiles that appeared to be corpora amylacea. Distinguishing the corpora amylacea is important because they stain with many antibodies and could potentially be confused with axonal swellings (Fig. 1I and Table 3 ).
Comparisons of Patient Age, Postinjury Survival, and ApoE Genotype With Pathological Findings
No obvious relationship was found between the extent of the damage demonstrated by immunoreactivity in the axonal bulbs, plaques, neurons, and corpora amylacea, and the age, postinjury survival, or ApoE genotype of the brain-injured patients (Table 3) . It should be noted, however, that the total number of cases was relatively small for such comparisons. Nonetheless, a consistent association was found; in all cases in which A␤ plaques were identified, A␤ accumulation in damaged axons was also observed.
Discussion
In this report we present the first evidence of extensive A␤ accumulation in the terminal ends of disconnected axons after brain trauma in humans. Many of these immunoreactive axon profiles were found close to A␤ plaques or surrounded by A␤ staining that spread out into the tissue. In addition, A␤ immunoreactivity in damaged axons was consistently found to colocalize with staining for APP and NF protein. On the basis of these data we can infer that damaged axons may represent a key source of A␤ peptides for plaque formation after TBI in humans.
Axonal injury is one of the most important and most common features of diffuse TBI in humans. 1, 24 It has been well established that damage to axons can lead to impaired axonal transport and massive accumulation of proteins, including APP. 4, 10, 15, 16, 22, 27, 29 Although it has long been suspected that this accumulated APP could provide an ample substrate for A␤ production, 10, 16, 22, 25 only recently has A␤ been identified in damaged axons after inertial brain trauma in the pig and following head impact in the rat. 9, 23, 27 In both the pig model and the present study, A␤ was found to coaccumulate with APP in swollen axons throughout the injured brain. Nevertheless, A␤ was not found in all damaged axons. Typically, A␤ was identified in axon bulbs (discrete terminal swellings of disconnected axons), but not in elongated varicose axonal swellings that were otherwise visualized by APP staining. Thus, impaired axonal transport alone does not appear to account for the accumulation of A␤. Rather, axon disconnection may favor processes that lead to the production and/or accumulation of A␤, such as enhanced proteolysis of APP. Whether these processes are active in all patients with axonal damage remains to be determined. In the present study, brain sections from three patients revealed extensive areas of axonal injury with no A␤ immunoreactivity. Nonetheless, this observation does not rule out the possibility that A␤ could have accumulated in regions that were not examined or that A␤ formation and accumulation may be more delayed in some patients.
It is important to consider that the large pool of axonal A␤ may play a role in further pathogenesis after brain trauma. During lysis or leakage of axonal bulbs, A␤ may be released into surrounding tissue and cerebrospinal fluid. This process may partially account for recent reports in which large increases in A␤ peptides have been described in the cerebrospinal fluid of brain-injured patients. 3, 17 Conceivably, released axonal A␤ could aggregate in the tissue parenchyma, potentially representing a mechanism of A␤ 
* Plaques, axonal bulbs, and corpora amylacea were counted in different fields and average immunoreactive plaques and bulbs were classified as follows: ϩ, less than five deposits; ϩϩ, six to 15 deposits; ϩϩϩ, more than 15 deposits. Abbreviation: NFP = NF protein.
plaque formation after brain trauma. In the present study, only patients with substantial A␤ accumulation in axons also demonstrated a large number of A␤ plaques. Although relatively few A␤ plaques were found in the pig model of inertial brain injury, those plaques were consistently found close to axonal A␤ accumulations. 23 It is not presently clear why humans apparently have an increased susceptibility, compared with pigs, to form A␤ plaques after trauma; however, species-specific amino acid sequencing and processing of APP may partially account for this difference, as has been previously suggested with regard to rodents. 16 It is also important to note that our current data corroborate earlier findings of A␤ plaque formation shortly after brain trauma in humans. 6, 19 There has been some conflict in this area, with one study failing to elucidate A␤ plaques in brain-injured patients. 2 Although reasons for this disparity are not clear, differences in immunohistochemical analyses between laboratories may have accounted for variable outcomes. In the present study we used a panel of antibodies specific to A␤ epitopes in combination with antigen retrieval techniques to confirm the presence of A␤ plaques, as well as to identify A␤ accumulations in damaged axons.
Previously, it has been found that patients with AD who have the ApoE ⑀4 allele have increased A␤ deposits. 20 Individuals with ApoE ⑀4 also have a worsened outcome after TBI 7, 28 and are more likely to have A␤ plaques in their brains shortly following injury. 8, 14 Because of the limited number of cases, the present data do not demonstrate a relationship between ApoE genotype and A␤ plaques following brain trauma. Nonetheless, in all cases in which A␤ plaques were identified, extensive A␤ accumulation in damaged axons was also found, often close by. This observation supports a potential link between these two posttrauma pathological conditions.
Conclusions
It is recognized that axonal injury is one of the most common and extensive pathological conditions of brain trauma in humans. Accordingly, our current finding of A␤ accumu-FIG. 1. Representative photomicrographs of APP, A␤, and NF protein accumulations in the brain following TBI in patients. The APP and NF protein accumulations in swollen axons are shown as darkly staining immunoreactivity to the antibodies 22C11(A) and N52 (B and C). The A␤ plaque formations are observed in cortical gray matter stained by 6F/3D antibody (D). In the white matter, A␤ plaques are found close to axonal bulbs, which also stain for A␤, by applying the antibodies 13335 and A␤17 (arrows in E and F, respectively). Immunoreactivity for NF protein was also occasionally detected in neurons (G and H) and in corpora amylacea (I). Scale bars = 20 m. lation in damaged axons reveals a potentially important reservoir of A␤ that can form within days after brain trauma. Release of axonal A␤ may represent a key mechanism leading to further pathogenesis, including A␤ plaque formation. Ultimately, this process may play a role in the link between brain trauma and the development of AD.
